Scientific Publications

SELECTED JOURNAL ARTICLES
HIV/AIDS and AV-HALTs

De Forni, D., Stevens, MR., and Lori, F. Strategies to improve efficacy and safety of a novel class of antiviral hyper-activation-limiting therapeutic agents: the VS411 model in HIV/AIDS. British Journal of Pharmacology 161(4):830-43, 2010.

Lori, F. Treating HIV/AIDS by reducing immune system activation: the paradox of immune deficiency and immune hyperactivation. Current Opinion in HIV and AIDS 3:99-103, 2008.

Foli, Z., Maiocchi, M.A., Lisziewicz, J., and Lori, F. A Checkpoint in the Cell Cycle Progression as a Therapeutic Target to Inhibit HIV Replication. J Infect Dis. 196(9):1409-15, 2007.

Maserati, R., Foli, A., Tomasoni, L., Sighinolfi, L., Maggiolo, F., Sacchini, D., Di Pietro, M., Bertelli, D., Tinelli, C., and Lori, F.: Effects of Structured Treatment Interruptions on Metabolilc, Anthrompometric, Immunologic, and Quality of Life Outcomes in HIV-Positive Adults on HAART. Current HIV Research 5:337-43, 2007.

Lori, F., Foli, A., Kelly, L.M., Lisziewicz, J.: ViroStatics: A New Class of Anti-HIV Drugs. Curr Med Chem. 14: 233-41, 2007.

Lori, F., Foli, A., Lisziewicz, J.: Stopping HAART temporarily in the absence of virus rebound: exploring new HIV treatment options. Current Opinion in HIV and AIDS 2:14-20, 2007.

Lori, F., Foli, A., Groff, A., Lova, L. MS, Whitman, L., Bakare, N., Pollard, R.B., Lisziewicz, J.: Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic ('virostatic') mechanisms AIDS. Jul 22;19(11): 1173-8, 2005.

Lori, F., Pollard, R.B., Whitman, L., Bakare, N., Blick, G., Shalit, P., Foli, A., Peterson, D., Tennenberg, A., Schrader, S., Rashbaum, B., Farthing, C., Herman, D., Norris, D., Greiger, P., Frank, I., Groff, A., Lova, L., Asmuth, D., Lisziewicz, J.: Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency. AIDS Res Hum Retroviruses. 21(4): 263-272, 2005.

Lova, L., Groff, A., Ravot, E., Comolli, G., Xu, J., Whitman, L., Lewis, M., Foli, A., Lisziewicz, J., Lori, F.: Hydroxyurea exerts a cytostatic but not immunosuppressive effect on T lymphocytes. AIDS, Jan 28;19(2): 137-144, 2005.

PHPC Assay

Calarota, S.A., Foli, A., Maserati, R., Baldanti, F., Paolucci, S., Young, M.A., Tsoukas, C.M., Lisziewicz, J., and Lori, F. HIV-1-specific T-cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals. J Immunol 180:5907-5915, 2008.

SELECTED POSTERS AND PRESENTATIONS
HIV/AIDS and AV-HALTs

6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 17-20 July 2011, Rome, Italy
Lori F., Baev D.V., De Forni D., Katabira E., Maserati R., Cahn P.,  Poddesu B.,  Stevens M.R. Depletion of naïve CD4+T cell compartment by immune hyperactivation can be rapidly reversed by AntiViral-HyperActivation Limiting Therapeutics (AV-HALTs). Late Breaker Presentation WELBX03
- Late Breaker Presentation WELBX03

De Forni D., Katabira E., Maserati R., Cahn P., Baev D.V., Poddesu B., Stevens M.R., Lori F. Decrease of Ki-67 proliferation marker correlates with CD4+cell count increase and predicts viral load suppression following 4 week AV-HALT treatment: Clinical Proof of Concept of an immunological predictive marker. Poster MOPE 139
- Poster MOPE139

Baev D.V., Katabira E., Maserati R., Cahn P., De Forni D., Poddesu B., Stevens M.R., Lori F. Ki-67 proliferation marker significantly decreases despite incomplete virus suppression in both naïve and central memory CD4+T cell subsets following 4-week AV-HALT treatment:A novel strategy to reduce viral reservoirs and immune system hyperactivation. Poster MOPE 267
- Poster MOPE 267

18th Conference on Retroviruses and Opportunistic Infections, 27 February-3 March, 2011, Boston, U.S.A.
Baev D., Katabira E., Maserati R., Cahn P., De Forni D., Lisziewicz J., Stevens M., and Lori F. Prompt, significant reduction of activation and proliferation markers in CD4+ and CD8+ T cell subsets despite incomplete viral suppression: proof of concept for AV-HALTs: new class of anti-HIV therapeutics inhibiting both HIV replication and immune activation. Poster abstract 381.
- Poster abstract 381

XVIII International AIDS Conference, 18-23 July 2010, Vienna, Austria.
Baev, D., Calarota, S.A., Testori M., and Lori, F. Pre-treatment expression of Ki-67 proliferation marker predicts HIV-1 suppression after antiretroviral therapy. Poster abstract 5009.
- Poster  abstract 5009

Katabira, E., Cahn, P., Lange, J., Maserati, R., Baev, D., Calarota, S.A., De Forni, D., Stevens, M.R., Lisziewicz, J., Lori, F., for the VS411 Study Group. Both immune activation and viral load are reduced within 28 days by VS411, the first antiviral-hyperactivation limiting therapeutic (AV-HALT). A phase II study. Poster abstract 4916.
- Poster abstract 4916

HIV DART 2008: frontiers in drug development for antiretroviral therapies, 9-12 December 2008, Rio Grande, Puerto Rico
Lori F., De Forni D., Stevens M. Development of VS411, a Virostatic fixed-dose combination (FDC) designed to inhibit both HIV and immune hyperactivation. Poster abstract 11.

PHPC Assay

European AIDS Conference / EACS, Oct 24-27, 2007 in Madrid, Spain
S. A. Calarota, A. Foli, R. Maserati, V. La Rosa, F. Baldanti, S. Paolucci, C. M. Tsoukas, J. Lisziewicz, F. Lori, "Antigen-specific T Lymphocytes with High Proliferative Capacity Inversely Correlate with Viral Replication in Chronically Untreated HIV-1-infected Individuals" - (Poster # P2.4/02/BPD)